Investing.com -- Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) stock surged 14.9% on Thursday after the company announced positive preliminary results from its Phase 2 trial of setmelanotide in patients ...

BOSTON - Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced Thursday preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), showing ...

-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising ...

The Food and Drug Administration (FDA) has extended the review period for setmelanotide in the treatment of acquired hypothalamic obesity. Setmelanotide, a melanocortin-4 receptor agonist, is ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2025 Earnings Call Transcript November 4, 2025 Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.82 EPS, expectations were ...

BOSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...

It appears that complaints such as those made by New Ulm Mayor Carl Wyczawski against th allocation of 1975 federal community development funds in Minnesota have done some good. Certain changes will ...

Several local students have achieved the dean’s list at Kutztown University. To be eligible for the dean’s list, an undergraduate student must be registered for at least 12 credits and have a minimum ...

MEEKER | David Cole stood tall and proud as he was inducted into the Colorado Northwestern Community College (CNCC) Hall of Fame Saturday, Sept. 27, surrounded by friends, family and colleagues. David ...

A Prescription Drug User Fee Act target date of December 20, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) ...